Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2012, Article ID 160830, 12 pages
Review Article

Theranostic Implications of Nanotechnology in Multiple Sclerosis: A Future Perspective

1Department of Biotechnology, University of Pune, Ganeshkhind Road, Pune 411 007, India
2Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Room 2145, 110 8th Street, Troy, NY 12180, USA
3Department of Applied Sciences, Maharashtra Academy of Engineering, Alandi (D), Pune 412 105, India
4Centre for Vascular Disease, University of Ferrara, 41100 Ferrara, Italy

Received 9 August 2012; Accepted 9 November 2012

Academic Editor: Pietro Invernizzi

Copyright © 2012 Ajay Vikram Singh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Multiple Sclerosis is a multifactorial disease with several pathogenic mechanisms and pathways. Successful MS management and medical care requires early accurate diagnosis along with specific treatment protocols based upon multifunctional nanotechnology approach. This paper highlights advances in nanotechnology that have enabled the clinician to target the brain and CNS in patient with multiple sclerosis with nanoparticles having therapeutic and imaging components. The multipartite theranostic (thera(py) + (diag)nostics) approach puts forth strong implications for medical care and cure in MS. The current nanotheranostics utilize tamed drug vehicles and contain cargo, targeting ligands, and imaging labels for delivery to specific tissues, cells, or subcellular components. A brief overview of nonsurgical nanorepair advances as future perspective is also described. Considering the potential inflammatory triggers in MS pathogenesis, a multifunctional nanotechnology approach will be needed for the prognosis.